Murex Announces Strategic, Multi-Year, Global AWS Collaboration Agreement to Accelerate Ambitious Managed Services Program
29.9.2025 10:45:00 EEST | Business Wire | Press release
Murex, a global leader in enterprise-wide, cross-asset financial technology solutions used by sell-side and buy-side capital markets players, and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced a multi-year strategic collaboration agreement, expanding the long partnership between both organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250929521787/en/
The agreement is the result of many months of intensive technical collaboration between both organizations, and it allows Murex to further scale its MX.3 platform into a suite of managed services powered by AWS. Financial institutions can already access unrivaled functional coverage while benefiting from the highest security standards, servicing operational excellence, and the ability to meet evolving regulatory requirements.
The collaboration accelerates the initial deployment and facilitates the frequent upgrade of Murex’s solutions for financial institutions worldwide. The agreement specifically expands Murex’s software-as-a-service offering, MXSaaS, and innovative cloud-native solution XVA as a Service through flexible turnkey services on AWS. XVA as a Service particularly leverages AWS elastic computing to deliver scalable, sophisticated risk analytics to its clients. Murex has added four new customers to MXSaaS since the collaboration agreement was signed in June, proving the value of the AWS collaboration and consolidating MXSaaS as a mature, well-established service.
By running on AWS, Murex Managed Services gain enhanced agility, flexibility and resiliency, across Murex's solution suite, optimizing client experiences through technical process automation, performance monitoring, and proactive incident management. Benefits include runtime trends identification, accelerated time-to-market and service disruption prevention.
As part of this strategic shift, Murex is investing significantly in scaling MXSaaS operations. Its aim is to equip FinOps and DevOps practices with state-of-the-art technologies and grow its global team to serve a large percentage of its existing and future customer base.
“Financial institutions across banking, capital markets, and asset management are increasingly seeking cloud-based solutions that can reduce operational complexity while providing access to innovation,” said Charlie Sanderson, Director, EMEA Technology Partners, AWS. “This collaboration combines AWS’s proven infrastructure with Murex's capital markets solutions to help customers increase agility and time-to-market, while maintaining the highest levels of security, compliance, and efficiency.”
“Financial institutions face mounting pressure from macroeconomic volatility, regulatory demands and cybersecurity concerns,” said Elias Eddé, Murex CEO. "Running mission-critical trading and risk management platforms requires significant infrastructure investment and specialized resources to continuously maintain operational resilience and performance. Jointly with AWS, Murex delivers them as a service today powered by AWS, in a further extension of capabilities that Murex has developed over a long time with AWS.”
About MXSaaS
MXSaaS brings Murex’s capital markets platform, MX.3, into the cloud, where the entire MX.3 stack is fully managed by dedicated Murex experts, from infrastructure to upgrades. It is built for institutions that need to accelerate time-to-market, reduce operational burden and focus on strategic growth. It allows them to gain an always-on, always-current trading and risk platform that scales with their ambitions. Learn more about MXSaaS.
About XVA as a Service
XVA as a Service is a comprehensive, cloud-native SaaS solution that delivers the full power of MX.3 for XVA Management capabilities. It enables precise trade-level exposure calculations; collateral projections; tailored funding logic; and effective management of the total cost of XVA trading across asset classes. The solution complements existing MX.3 instances, and helps institutions of all sizes streamline operations, reduce costs and stay ahead of evolving market and regulatory demands.
About Murex
Murex provides enterprise-wide, cross-asset financial technology solutions to sell-side and buy-side capital markets players. With more than 60,000 daily users in 65 countries, its cross-function platform, MX.3, supports trading, treasury, risk, post-trade operations, as well as end-to-end investment management operations for private and public assets. This helps clients better meet regulatory requirements, manage enterprise-wide risk, and control IT costs. Learn more at http://www.murex.com.
About Amazon Web Services
Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 120 Availability Zones within 38 geographic regions, with announced plans for 10 more Availability Zones and three more AWS Regions in Chile, the Kingdom of Saudi Arabia, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth's Most Customer-Centric Company, Earth's Best Employer, and Earth's Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit https://amazon.com/about and follow https://twitter.com/amazonnews.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250929521787/en/
Contacts
Murex Contact
Aspectus Group
Amelia Fillis
amelia.fillis@aspectusgroup.com
+44 (0) 7450-840-559
AWS Contact
Naomi Little
njlittle@amazon.com
+1 771 233 2089
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom